Please login to the form below

Not currently logged in
Email:
Password:

overactive bladder

This page shows the latest overactive bladder news and features for those working in and with pharma, biotech and healthcare.

Urovant slips on phase 3 incontinence drug data

Urovant slips on phase 3 incontinence drug data

The phase 3 EMPOWUR trial of vibegron in patients with incontinence caused by overactive bladder (OAB) showed that the beta-3 adrenergic agonist performed significantly better than placebo on the two

Latest news

More from news
Approximately 4 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new

  • Allergan and taking a specialised approach Allergan and taking a specialised approach

    In addition to migraine and adult spasticity, its approved indications include overactive bladder, muscle stiffness in elbow, wrist and fingers, muscle problems in the eye, crow's feet lines and severe

  • Interview: Kay Drake and Naoki Okamura, Astellas Interview: Kay Drake and Naoki Okamura, Astellas

    For example, we are a GCL in urology; we have Vesicare, which has 40 per cent market share in the overactive bladder (OAB) market. ... From an OAB perspective, we support the Bladder and Bowel Foundation here in the UK, which provides a patient advice

  • Show stopper exposes taboo

    As part of a national campaign called A Matter of Urgency’, the show-stopping garden was designed to raise awareness of Overactive Bladder which affects nearly one in five people in ... Nearly one in five people in the UK over 40 have an overactive

  • Interview: Ken Jones, Astellas Pharma Europe Interview: Ken Jones, Astellas Pharma Europe

    Urology is a key strategic area for Astellas and we have a strong pipeline in this therapy area; we are currently getting prepared with Mirabegron, a drug to treat overactive bladder,

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • emotive boosts health economics and outcomes research team

    His MSc project involved performing a health economic evaluation of the cost-effectiveness of different overactive bladder treatments available in the UK. ... The appointment of Trishal, with his specific expertise in visual science and overactive bladder

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics